Skip to main content

Table 1 Overview of variables, concepts, measures, and time points

From: Cognitive behavioural therapy for psychopathology in relatives of missing persons: study protocol for a pilot randomised controlled trial

Variable

Concept

Measure

Time points

Primary outcome measures

Severity of PCBD symptoms

ICG

T0, T0.1, T1, FU1, FU2

Secondary outcome measures

Severity of PTSD symptoms

PCL-5

T0, T0.1, T1, FU1, FU2

 

Severity of depressive symptoms

IDS-SR

T0, T0.1, T1, FU1, FU2

 

Extent of mindfulness

SMQ

T0, T0.1, T1, FU1, FU2

Mediator

Severity of grief cognitions

GCQ

T0, T0.1, T1, FU1, FU2

 

Severity of rumination

RRS

T0, T0.1, T1, FU1, FU2

 

Severity of repetitive negative thinking

PTQ

T0, T0.1, T1, FU1, FU2

 

Ability to be self-compassionate

SCS

T0, T0.1, T1, FU1, FU2

 

Severity of intrusive memories

TMQ

T0, T0.1, T1, FU1, FU2

 

Severity of avoidance behaviour

DAAPGQ

T0, T0.1, T1, FU1, FU2

Process of change session by session

Ability to be self-compassionate

SCS-SF

Start of each treatment session

 

Severity of intrusive memories and images

Intrusive memories and images vas

Start of each treatment session

 

Frequency of repetitive negative thinking

RNT vas

Start of each treatment session

Other variables

Sociodemographic information

 

T0

 

Evaluation of the treatment and reason(s) for drop-out

 

T1

  1. ICG Inventory of Complicated Grief, PCL-5 Posttraumatic Stress Disorder Checklist for DSM-5, IDS-SR Inventory of Depressive Symptomatology—Self-Report, SMQ Southampton Mindfulness Questionnaire, GCQ Grief Cognition Questionnaire, RRS Ruminative Response Scale, PTQ Perseverative Thinking Questionnaire, SCS Self-Compassion Scale, TMQ Trauma Memory Questionnaire, DAAPGQ Depressive and Anxious Avoidance in Prolonged Grief Questionnaire, SCS-SF Self-Compassion Scale – Short Form, RNT vas Repetitive Negative Thinking visual analogue scale, T0 baseline measure, T1 post-treatment assessment, T0.1 post-waiting period measure, FU1 follow-up measure 1, FU2 follow-up measure 2